Interferon Intron

USA interferon alfa-2b interferon Intron A Alfatronol, Depointerferon alpha, Viraferon Recombinant IFN-alpha2b from the clone HifSN206 with substitution at 23 (Arg) and 34 (His) from an E. coli expression system Anit-cancer, hepatitis... 

Interferon INTRON A (recombinant interferon a-2b) Schering-Plongh Corp. 

Interferon Intron A Biogen, Scher- 1986 IFN-a-2b Chronic hepatitis B Bacterial 2001... 

Which statement is the scientific rationale for administering the biologic response modifier interferon (Intron A) to a client diagnosed with hepatitis C ... 

The subcutaneous dose of interferon alfa-2b (Intron A) in patients who are HBsAg-positive is either 5 million units daily (better tolerated) or 10 million units three times weekly. The dose for HBsAg-negative patients is 5 to 6 million units three times weekly. The approved dose for pegylated interferon alfa-2a (Pegasys) for chronic hepatitis B is 180 meg subcutaneously once weekly. Interferon doses may need to be adjusted in patients with renal impairment. 

Interferon alfa-2a (Roferon A), interferon alfa-2b (Intron-A), and interferon alfacon-1 (Infergen) are approved for chronic hepatitis C. However, they are not prescribed alone because only 12% to 16% of patients achieve a sustained virologic response (SVR). Adding ribavirin, a synthetic guanosine analogue that inhibits viral polymerase, increases the SVR rate to 35% to 45%. 

Intron A interferon a-2b Schering-Plough Hairy cell leukemia, genital warts, AIDS-related Kaposi s sarcoma, hepatitis C, hepatitis B, malignant melanoma, follicular lymphoma in conjunction with chemotherapy... 

Interferon alfa-2a Interferon alfa-2b 18 million IU 18 million IU 209.58 218.04 Roferon-A Intron-A ... 

Interferon-a Hepatitis B and C Pegasys, Peg-Intron, Ribetron, Copegus... 

PEG-Intron PEG-Intron is used for the treatment of hepatitis C. The product consists of a covalent conjugate of the recombinant interferon- -2b with monomethoxy polyethylene glycol (PEG) supplied in vials with 74/rg, 118.4/rg, 177.6/rg, or 222/rg of the active ingredient and 1.11 mg sodium phosphate (dibasic,anhydrous),l.ll mg sodium phosphate (monobasic, dihydrate), 59.2 mg sucrose, and 0.074mg polysorbate 80. The powder is reconstituted with sterile water-for-injection. 

Interferon-a-2b Intron A Schering Plough Expired Expired... 

The market for biopharmaceuticals is over 90 bilhon. The most well-known products of the modem biotechnology industry are the mammahan polypeptides such as erythropoietin (EPO) with an 14 bilhon market human insuhn (Novolin and Humuhn), 5.6 bilhon interferon alpha (Intron... 

Peg Interferon Alfa 2b (PEG-Intron) [Antiviral/ Immunomodulator] WARNING Can cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disord s. Monitor pts closely Uses Rx Hep C Action Immune modulation Dose 1 mcg/kg/wk SQ 1.5 mcg/kg/wk combined w/ ribavirin Caution [C, X if used w/ ribavirin /-] w/ Hx psychiatric Contra Autoimmune H, decompensated Uvct Dz, hemoglobinopathy Disp Vials 50, 80, 120, 150 mcg/0.5 mL Redipen 50, 80,120,150 mcg/5 mL reconstitute w/ 0.7 mL w/ sterile water SE D ession, insomnia, suicidal behavior, GI upset, neutropenia, thrombocytopenia, alopecia, pruritus Interactions t Myelosuppression W/ antineoplastics t effects OF doxorubicin, theophylline t neurotox W7 vinblastine EMS See Peg Interf on Alfa-2a may cause flu-like Sxs... 

Intron A (Sobering Plough) Interferon-a (treatment of leukaemia) 1.4... 

Interferons a-2b (Intron-A), a-nl, and a-n3 (Alferon N) have both intrinsic antiviral effects and antiproliferative and immunomodulatory actions. These interferons are approved for intralesional therapy of refractory or recurrent condylomata (genital warts). Toxicities include flulike symptoms, nausea, depression of the white blood cell count, and mild diminution in hematocrit. 

Interferon alfa-2b (Intron A) is a recombinant DNA product derived from the interferon alfa-2b gene of human white blood cells. Its mechanism of antitumor action involves binding to a plasma membrane receptor but is otherwise poorly understood. Its serum half-life is 2 to 3 hours after parenteral administration. 

E. Therapeutic response Efficacy of Infergen therapy was determined by measurement of serum alanine aminotransferase (ALT) concentrations at the end of therapy (24 weeks) and following 24 weeks of observation after the end of treatment of adults with chronic HCV infection. Serum HCV RNA was also assessed using a quantitative reverse transcriptase polymerase chain reaction (RT-PCR). At the end of 24 weeks of treatment, ALT normalization was observed in 39% of patients on Infergen and in 35% of patients on interferon alfa-2b Intron A). Only 17% of patients in each group... 

F. Role in therapy According to Micromedex, Roferon-A is recommended as the drug of choice in renal carcinoma and the chronic phase of chronic myelogenous leukemia. The role of Gleevec (Ima-tinib) in CML is yet to be determined, but it may replace the use of interferon alfa-2a. Roferon-A is an alternative (for unrespon-sive/intolerant patients) to current regimens of choice in hairy-cell leukemia, multiple myeloma, metastatic melanoma, and AIDS-related Kaposi s sarcoma. Other alpha interferons appear to have similar efficacy and can be used in lieu of Roferon-A in some instances. In particular, interferon alfa-2b (Intron) can be considered to have the same role as interferon alfa-2a in chronic hepatitis C, Kaposi s sarcoma, and hairy-cell leukemia. 

A. General description Intron A (interferon alfa-2b recombinant) is a recombi-nantly derived water-soluble protein with a molecular weight of 19.3 kDa. It is obtained from the bacterial fermentation of a strain of Escherichia coli bearing a genetically engineered plasmid containing an interferon alfa-2b gene from human leukocytes. 

Drug Interactions According to the product label, interactions between Intron A and other drugs have not been fully evaluated. Caution should be exercised when administering Intron A therapy in combination with other potentially myelo-suppressive agents such as zidovudine. Concomitant use of alfa interferon and theophylline decreases theophylline clearance, resulting in a 100% increase in serum theophylline levels. 

B. Indications and use PEG-Intron monotherapy is indicated for the treatment of chronic hepatitis C in patients not previously treated with interferon alfa who have compensated liver disease and are at least 18 years of age. 

Pharmacokinetics Pegylation of interferon alfa-2b produces a product whose clearance is substantially lower that than of nonpegylated interferon alfa-2b. The mean absorption half-life of peginterferon alfa-2b following a single subcutaneous injection of PEG-Intron is 4.6 hours. Time to peak concentration is variable and may... 

E. Therapeutic response A randomized trial compared treatment with PEG-Intron, once weekly, to treatment with Intron A (interferon alfa-2b), three times weekly, in 1219 previously untreated adults with chronic hepatitis from HCV infection. Patients were treated for 48 weeks. Response to treatment was defined as undetectable HCV RNA (less than 100 copies per ml) and normalization of the liver enzyme alanine aminotransferase (ALT) at 24 weeks post-treatment. Response rates to the l.Opg/kg PEG-Intron doses and to Intron A were 24% and 12%. Patients receiving PEG-Intron with viral genotype 1 had a response rate of 14%, while patients with other viral genotypes had a 45% response rate. 

Interferons and cytokines Interferon alfa-2b, human recombinant product produced in E. coli Intron A Lyophilized 5, 10,18,25, or 50MIUvial IM,SC, IV, intralesional... 

Interferons and cytokines Peginterferon aha-2b, human recombinant produced in E coli PEG-Intron 2ml lycophihzed powder-lOO, 160,240, 300 4g/ml sc... 

Interferons and cytokines Peginterferon aha-2b, PEG-modified human recombinant inteferon alfa-2b (Intron A, produced in E. coh) PEG-Intron Lyophilized 74,118,177, or 222 ig in 2 ml vial sc... 

Interferon alfa-2b, Intron A human recombinant product produced in E. coli... 

---